UM  > Faculty of Health Sciences
Nanomedicine-combined immunotherapy for cancer
Huang,Shigao1,2; Zhao,Qi1,2
Source PublicationCurrent Medicinal Chemistry

Background: Immunotherapy for cancer includes Chimeric Antigen Receptor (CAR)-T cells, CAR-natural Killer (NK) cells, PD1, and the PD-L1 inhibitor. However, the proportion of patients who respond to cancer immunotherapy is not satisfactory. Concurrently, nanotechnology has experienced a revolution in cancer diagnosis and therapy. There are few clinically approved nanoparticles that can selectively bind and target cancer cells and incorporate molecules, although many therapeutic nanocarriers have been approved for clinical use. There are no systematic reviews outlining how nanomedicine and immunotherapy are used in combination to treat cancer. Objective: This review aims to illustrate how nanomedicine and immunotherapy can be used for cancer treatment to overcome the limitations of the low proportion of patients who respond to cancer immunotherapy and the rarity of nanomaterials in clinical use. Methods: A literature review of MEDLINE, PubMed / PubMed Central, and Google Scholar was performed. We performed a structured search of literature reviews on nanoparticle drug-delivery systems, which included photodynamic therapy, photothermal therapy, photoacoustic therapy, and immunotherapy for cancer. Moreover, we detailed the advantages and disadvantages of the various nanoparticles incorporated with molecules to discuss the challenges and solutions associated with cancer treatment. Conclusion: This review identified the advantages and disadvantages associated with improving health care and outcomes. The findings of this review confirmed the importance of nanomedicine-combined immunotherapy for improving the efficacy of cancer treatment. It may become a new way to develop novel cancer therapeutics using nanomaterials to achieve synergistic anticancer immu-nity.

Keyword(Car)-t Cells Cancer Immunotherapy Car-nk Cells Drug Delivery Nanomedicine Synergistic Effect
URLView the original
Indexed BySCIE
WOS Research AreaBiochemistry & Molecular Biology ; Pharmacology & Pharmacy
WOS SubjectBiochemistry & Molecular Biology ; Chemistry, Medicinal ; Pharmacology & Pharmacy
WOS IDWOS:000581009700003
Fulltext Access
Citation statistics
Cited Times [WOS]:4   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Corresponding AuthorZhao,Qi
Affiliation1.Cancer Center,Faculty of Health Sciences,University of Macau,Taipa,China
2.Institute of Translational Medicine,Faculty of Health Sciences,University of Macau,Taipa,China
First Author AffilicationCancer Centre;  Faculty of Health Sciences
Corresponding Author AffilicationCancer Centre;  Faculty of Health Sciences
Recommended Citation
GB/T 7714
Huang,Shigao,Zhao,Qi. Nanomedicine-combined immunotherapy for cancer[J]. Current Medicinal Chemistry,2020,27(34):5716-5729.
APA Huang,Shigao,&Zhao,Qi.(2020).Nanomedicine-combined immunotherapy for cancer.Current Medicinal Chemistry,27(34),5716-5729.
MLA Huang,Shigao,et al."Nanomedicine-combined immunotherapy for cancer".Current Medicinal Chemistry 27.34(2020):5716-5729.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Huang,Shigao]'s Articles
[Zhao,Qi]'s Articles
Baidu academic
Similar articles in Baidu academic
[Huang,Shigao]'s Articles
[Zhao,Qi]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Huang,Shigao]'s Articles
[Zhao,Qi]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.